Compare · LONA vs RVMD
LONA vs RVMD
Side-by-side comparison of LeonaBio Inc. (LONA) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LONA and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $26.81B, about 342.7x LONA ($78.2M).
- Over the past year, LONA is up 198.2% and RVMD is up 226.0% - RVMD leads by 27.8 points.
- RVMD has been more active in the news (18 items in the past 4 weeks vs 14 for LONA).
- RVMD has more recent analyst coverage (25 ratings vs 2 for LONA).
- Company
- LeonaBio Inc.
- Revolution Medicines Inc.
- Price
- $8.32-2.12%
- $135.30+0.80%
- Market cap
- $78.2M
- $26.81B
- 1M return
- -10.25%
- +43.55%
- 1Y return
- +198.21%
- +226.02%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2020
- News (4w)
- 14
- 18
- Recent ratings
- 2
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest LONA
- LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
- Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio's Data
- SEC Form 4 filed by Panzara Michael A.
- SEC Form 4 filed by Church Kevin
- SEC Form 4 filed by Kosacz Barbara
- SEC Form 4 filed by Pickering Grant
- SEC Form 4 filed by Romano Kelly A
- SEC Form 4 filed by Johnson James A
- SEC Form 4 filed by Edelman Joseph
- SEC Form 4 filed by San Martin Javier
Latest RVMD
- Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
- Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
- Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
- SEC Form 4 filed by Goldsmith Mark A
- Revolution Medicines Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
- SEC Form 8-K filed by Revolution Medicines Inc.
- SEC Form 424B5 filed by Revolution Medicines Inc.
- SEC Form 424B5 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.